Global Glioblastoma Multiforme Therapeutics Market 2015-2019

多形性膠芽腫治療薬の世界市場2015-2019

◆タイトル:Global Glioblastoma Multiforme Therapeutics Market 2015-2019
◆商品コード:IRTNTR6606
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年7月29日
◆ページ数:81
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、多形性膠芽腫治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、多形性膠芽腫治療薬の世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Glioblastoma Multiforme
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.

Glioblastoma multiforme is the most common variant of brain tumor, and highly invasive in nature. It may turn up in the cerebrum, mostly in the frontal and temporal lobes, and seldom spreads in areas outside the brain. The tumor progresses rapidly, and is among the most difficult-to-treat cancer with limited treatment options.

Glioblastoma multiforme is also known as Class IV astrocytoma which has an unknown etiology, and is more frequent in men than women. Some of the common symptoms of glioblastoma multiforme are increased intracranial pressure resulting in nausea, vomiting, and headache, cognitive and visual impairment, motor dysfunction, seizures, loss in sensory functions, and changes in personality, mood or concentration. The condition can be broadly classified into two types, primary or de novo glioblastoma multiforme (which progresses very fast) and secondary glioblastoma multiforme (which is known to progress at a slower rate). Glioblastoma multiforme can be treated by chemotherapy, steroids, radiation therapy, proton therapy, surgical procedure, and immunotherapies, which are the emerging treatment options yet to hit the market.

Technavio analysts forecast the global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019.

[Covered in this Report]
The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme.

Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
• Oral
• Parenteral

Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
• Small Molecules
• Biologics

This report includes a discussion on the market in the following three regions:
• The Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries, such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India

Technavio also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

The Technavio report, namely Global Glioblastoma Multiforme Therapeutics Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. The report covers the Americas, and EMEA and APAC markets. It presents the market landscape and its growth prospects in the coming years.

[Key Regions]
• Americas
• EMEA
• APAC

[Key Vendors]
• Arbor Pharmaceuticals
• Bristol-Myers Squibb
• Eisai
• F. Hoffmann-La Roche
• Merck

[Other Prominent Vendors]
• AB Science
• Abbvie
• Actelion
• Activartis Biotech
• Advantagene
• Agenus
• Agios
• Amgen
• Angiochem
• Apogenix
• Axelar
• BioNTech
• Boehringer Ingelheim
• Boston Biomedical
• Bristol-Myers Squibb
• Celgene
• Celldex Therapeutics
• ChemoCentryx
• Cortice Biosciences
• CytoVac
• CytRx
• Deciphera
• Del Mar Pharmaceuticals
• Diffusion Pharmaceuticals
• DNATrix
• Eli Lilly
• Epitopoietic Research
• e-Therapeutics
• Exelixis
• G W Pharmaceuticals
• Genspera
• immatics
• ImmunoCellular Therapeutics
• Immunovaccine
• Intrexon
• IRAD Oncology
• Karyopharm Therapeutics
• Kite Pharma
• Life Science Pharmaceuticals
• Medicenna Therapeutics
• Merck
• Merrimack Pharmaceuticals
• Nektar Therapeutics
• Northwest Biotherapeutics
• Novartis
• Noxxon
• OncoSynergy
• Oncovir
• Ono Pharmaceutical
• Peregrine Pharmaceuticals
• Plexxikon
• Sanofi
• Seattle Genetics
• Spectrum Pharmaceuticals
• Stemline Therapeutics
• Tocagen
• Tracon Pharma
• TVAX Biomedical
• VBL Therapeutics
• Virttu Biologics
• Ziopharm Oncology

[Market Driver]
• Lack of Treatment Options for Glioblastoma Multiforme
• For a full and detailed list, view our report

[Market Challenge]
• Use of Off-label Drugs
• For a full and detailed list, view our report

[Market Trend]
• Prospective Entry of Novel Agents
• For a full and detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Market Landscape
06.1 Global Glioblastoma Multiforme Therapeutics Market
06.1.1 Market Overview
06.1.2 Market Size and Forecast
06.2 Five Forces Analysis

07.Market Segmentation by Route of Administration
07.1 Oral
07.2 Parenteral

08.Market Segmentation by Type of Molecule
08.1 Small Molecules
08.2 Biologics

09.Geographical Segmentation
09.1 Glioblastoma Multiforme Therapeutics Market in Americas
09.1.1 Market Overview
09.1.2 Market Size and Forecast
09.2 Glioblastoma Multiforme Therapeutics Market in EMEA
09.2.1 Market Overview
09.2.2 Market Size and Forecast
09.3 Glioblastoma Multiforme Therapeutics Market in APAC
09.3.1 Market Overview
09.3.2 Market Size and Forecast

10.Buying Criteria

11.Pipeline Portfolio

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Arbor Pharmaceuticals
18.2.2 Bristol-Myers Squibb
18.2.3 Eisai
18.2.4 F. Hoffmann-La Roche
18.2.5 Merck
18.3 Other and Possible Future Prominent Vendors

19.Key Vendor Analysis
19.1 Arbor Pharmaceuticals
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Recent Developments
19.1.5 SWOT Analysis
19.2 Bristol-Myers Squibb
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Key Product Offerings
19.2.4 Revenue by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Eisai
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Comparison between Revenue, Operating Income, and Net Income
19.3.4 Sales by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 F. Hoffmann-La Roche
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Information
19.4.8 SWOT Analysis
19.5 Merck
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Business Strategy
19.5.7 Key Developments
19.5.8 SWOT Analysis

20.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 3: Global Glioblastoma Multiforme Therapeutics Market 2014-2019 ($ millions)
Exhibit 4: Key Takeaways: Global Glioblastoma Multiforme Therapeutics Market
Exhibit 5: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Route of Administration
Exhibit 6: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Type of Molecule
Exhibit 7: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Geography 2014
Exhibit 8: Glioblastoma Multiforme Therapeutics Market in Americas 2014-2019 ($ millions)
Exhibit 9: Glioblastoma Multiforme Therapeutics Market in EMEA 2014-2019 ($ millions)
Exhibit 10: Glioblastoma Multiforme Therapeutics Market in APAC 2014-2019 ($ millions)
Exhibit 11: Global Glioblastoma Multiforme Therapeutics Market by Geography 2014-2019
Exhibit 12: Glioblastoma Multiforme: Pipeline Portfolio
Exhibit 13: Drug Candidates by Stage of Development (percentage)
Exhibit 14: Drivers of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 15: Challenges of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 16: Trends in the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 17: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 18: Bristol-Myers Squibb Co.: Geographical Segmentation by Revenue 2013
Exhibit 19: Eisai: Comparison between Revenue, Operating Income, and Net Income 2011-2013 ($ billions)
Exhibit 20: Eisai: Sales by Geography 2013 ($ billions)
Exhibit 21: F. Hoffmann-La Roche: Business Segmentation2013
Exhibit 22: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 23: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 24: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 25: Merck: Business Segmentation by Revenue 2013
Exhibit 26: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 27: Merck: Sales by Geography 2013



【掲載企業】

Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Ltd.

【資料のキーワード】

多形性膠芽腫、悪性脳腫瘍、治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[多形性膠芽腫治療薬の世界市場2015-2019] (Global Glioblastoma Multiforme Therapeutics Market 2015-2019 / IRTNTR6606)販売に関する免責事項
[多形性膠芽腫治療薬の世界市場2015-2019] (Global Glioblastoma Multiforme Therapeutics Market 2015-2019 / IRTNTR6606)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆